Moderna Stock Soars 90% After Phase 3 Cancer Vaccine Trial Success

PUBLISHED Aug 19, 2026, 7:36 PM ET

Moderna and Merck announced that their personalized mRNA cancer vaccine achieved its primary goal in a late-stage clinical trial. The study evaluated patients with high-risk melanoma who underwent complete surgical removal of their tumors. Administered alongside Merck immunotherapy drug Keytruda, the experimental vaccine significantly prolonged recurrence-free survival compared with Keytruda alone. The trial enrolled over one thousand participants across multiple global clinical trial sites. Executives from both companies stated that safety profiles remained consistent with earlier evaluations, showing no unexpected adverse events. Following the public disclosure, Moderna stock surge dramatically during premarket trading sessions, reflecting massive investor optimism. Merck shares also posted notable gains. Both pharmaceutical organizations plan to present comprehensive datasets at an upcoming international medical meeting. Regulatory submissions will follow shortly to pursue potential accelerated approval pathways with federal health agencies. The breakthrough represents a significant milestone for personalized mRNA therapeutics in oncology research worldwide today right now.

By Lauren Mitchell | JQJO News

Media Bias

Articles Published:: 31
Right Leaning:: 2
Left Leaning:: 0
Neutral:: 29

Explain Framing

Left: Emphasizes public health benefits and future accessibility for cancer patients. Center: Focuses strictly on clinical trial data, stock movements, and regulatory timelines. Right: Highlights corporate market gains, capitalist innovation, and biotech investment opportunities.